This guideline provides advice at all stages of the patient’s pathway of care, from primary prevention to early recognition, treatment and follow up. It does not address melanomas of non-cutaneous origin...
This is an updated guideline prepared for the British Association of Dermatologists (BAD) Clinical Standards Unit, made up of the Therapy & Guidelines Subcommittee (T&G) and the Audit & Clinical Standards Subcommittee (A&CS).
This guidance for the management of patients with chronic urticaria and angioedema has been prepared by the Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI)
The severity of a person's psoriasis before and during treatment should be assessed by considering the redness, thickness and scaliness of the plaques, the area of the body involved, and how the condition...
Psoriasis is a common, chronic inflammatory skin disease which typically follows a relapsing and remitting course, and is associated with joint disease in approximately 25% of patients.
To provide the dermatologist a guide focuses specifically on the diagnosis and management of the diseases most often found in patients with psoriasis.
A readily accessible summary for PCPs of the current evidence base and practical guidance on best practice in a number of psoriasis scenarios, from the UK's National Institute for Health and Care Excellence (NICE).
This document contains a single pathway diagram and uses numbering to link the boxes to the associated recommendations.
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.